December, 2024

article thumbnail

Set the Data Free: Break the Chains of Information Silos

MedCity News

When you combine clean data with longitudinal patient records and transparent access — that’s when you start seeing real transformation in care delivery. The post Set the Data Free: Break the Chains of Information Silos appeared first on MedCity News.

Patients 123
article thumbnail

RFK Jr. could 'cost lives in this country' if he pursues changes to US vaccine policy, Gottlieb says

Fierce Pharma

Robert F. Kennedy Jr.’s appointment last month to lead the U.S. Department of Health and Human Services immediately sent waves of speculation swirling throughout the biopharma industry. | The former FDA Commissioner pointed to the threat of measles if vaccination rates were to decline by 5%.

article thumbnail

Is Your SEO Strategy Outdated? The Critical Shift to AI and Intent-Driven Search in Healthcare

Healthcare Success

Did you know Google changes its algorithm up to 200 times a day? Yet many healthcare organizations still rely on SEO strategies and tactics that were "best practices" a decade ago. Its no surprise that countless healthcare providers and other businesses are seeing drops in rankings and traffic after Google's Helpful Content Update. To help you navigate these changes and learn what you need to update, I invite you to listen to this podcast featuring Brandon Schakola.

article thumbnail

Genmab expands its pipeline with $630m Scancell deal

pharmaphorum

Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.

129
129
article thumbnail

AI in Marketing & Sales: Today’s Tools, Tomorrow’s Potential

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

article thumbnail

The 2025 Pharma Toolkit for Virtual Medical Education

Impetus Digital

Pharma-exclusive Webinar: The 2025 Pharma Toolkit for Virtual Medical Education About the webinar Step into the future of medical education with our exclusive webinar series from February 25-26, designed specifically for Pharma leaders. This transformative series will showcase the 2025 Pharma Toolkit for Virtual Medical Education, revealing groundbreaking virtual tools and strategies set to revolutionize how we engage and educate HCPs, patients, and teams.

Education 107
article thumbnail

Reprieve for Chinese biotechs as BIOSECURE Act left out of key bill

Pharmaceutical Technology

Shares in WuXi AppTec, one of those implicated in the Chinese biotech blacklisting legislation, surged following the omission.

122
122

More Trending

article thumbnail

Eli Lilly's Zepbound defeats Novo Nordisk's Wegovy in head-to-head weight loss trial

Fierce Pharma

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.

Marketing 286
article thumbnail

A biotech’s race to tackle the most severe hepatitis

PharmaVoice

Bluejay Therapeutics is one of just a handful of companies developing treatments for hepatitis D.

111
111
article thumbnail

Deadline looms for post-Brexit label changes for UK meds

pharmaphorum

The MHRA has reminded pharma companies that from 1st January all medicines sold in the UK will have to comply with new labelling requirements

Medicine 125
article thumbnail

Antag Therapeutics secures €80 million in weight loss therapy financing

PharmaTimes

Versant Ventures leads investment round to advance drug

Leads 110
article thumbnail

5 Ways You Can Win Faster with Gen AI in Sales

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

article thumbnail

Novo gets the green light for once-daily haemophilia drug following setbacks 

Pharmaceutical Technology

The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.

FDA 105
article thumbnail

Axsome Aims for FDA Filing in Alzheimer’s Agitation Despite Mixed Bag of Phase 3 Data

MedCity News

One Phase 3 test of Auvelity met its main goal in Alzheimers agitation while the drugs other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimers agitation drug. The post Axsome Aims for FDA Filing in Alzheimers Agitation Despite Mixed Bag of Phase 3 Data appeared first on MedCity News.

FDA 113
article thumbnail

After studies flag possible link between Novo's Ozempic and rare eye disorder, Danish agency calls for probe

Fierce Pharma

Its not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisks diabetes superstar Ozempic and blindness? | After the recent release of two independent studies from the University of Southern Denmark suggested the use of Ozempic increases patients' chances of developing a rare eye disorder, the Danish Medicines Agency has asked European officials to investigate.

Medicine 272
article thumbnail

Pharmapack Europe 2025: Eco barrier packaging to launch

European Pharmaceutical Review

LOG Pharma Primary Packaging is set to present its new barrier eco line at Pharmapack Europe 2025. The new bottles for pharmaceuticals offer optimal oxygen scavenging. Our R&D team has developed a series of barrier bottles that provide exceptional protection against oxygen and moisture while being environmentally friendly and reducing costs significantly, stated LOGs Chief Executive Officer Shaul Bassi.

Pharma 105
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Novartis pays $1bn upfront for Huntington's drug from PTC

pharmaphorum

Novartis has made a return to the Huntington's disease stage by licensing an oral mRNA splicer from PTC Therapeutics for $1 billion upfront

111
111
article thumbnail

Pharma giants vie for oral GLP-1R approval

PharmaTimes

Race to create first oral drug for obesity intensifies

Pharma 110
article thumbnail

FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea

Pharmaceutical Technology

Lillys Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.

article thumbnail

Unlocking AI Explainability for Trustworthy Healthcare

MedCity News

AI should augment, not replace, human provider expertise. Explainability empowers healthcare professionals to work in tandem with AI, ensuring that patients receive the most accurate and informed care. The post Unlocking AI Explainability for Trustworthy Healthcare appeared first on MedCity News.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

After Moderna's pediatric RSV vaccine trial hold, expert panel says more testing is needed

Fierce Pharma

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that involve young children, experts from an FDA advisory panel expressed their | An FDA advisory committeeexamining the halt of a trial of two Moderna respiratory syncytial virus (RSV) vaccines because of severe lower respiratory tract infections (LRTIs)echoed frustration in knowledge gaps about the disease and said that more testing is needed.

FDA 284
article thumbnail

With Makary set to face FDA commissioner hearings, how deep do his industry ties run?

PharmaVoice

Dr. Marty Makary’s conflicts of interest could come into question before he is confirmed as the next FDA commissioner.

FDA 106
article thumbnail

Orexo exits depression DTx alliance with GAIA

pharmaphorum

Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.

111
111
article thumbnail

Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis

PharmaTimes

New cell therapy shows potential in treating advanced blood disorder

109
109
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset

Pharmaceutical Technology

MSD has entered an exclusive global licence agreement with Hansoh Pharma for a preclinical oral small molecule GLP-1RA.

Pharma 105
article thumbnail

Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages

MedCity News

Arcellxs cell therapy for multiple myeloma has shown no signs of the parkinsonism complication observed in clinical testing of Carvykti, a rival product from partners Johnson & Johnon and Legend Biotech. Arcellx is developing its CAR T-treatment under a partnership with Gilead Sciences. The post Safety Stands Out in Arcellx Cell Therapys ASH Data, But Dont Overlook Manufacturing Advantages appeared first on MedCity News.

Safety 116
article thumbnail

AstraZeneca's Enhertu and Akeso's bispecifics win national coverage in China as CAR-T therapies miss out again

Fierce Pharma

AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the count | AstraZeneca’s Daiichi Sankyo-partnered antibody-drug conjugate Enhertu has made it onto China’s national insurance program despite the star med being a part of an ongoing investigation in the country.

Insurance 253
article thumbnail

Nanoparticle drug delivery innovation could enhance drug development

European Pharmaceutical Review

Researchers in Australia have created an innovative drug delivery system that utilises a metalbiomolecule network (MBN) comprising of non-toxic metal ions together with phosphonate biomolecules, eg, DNA. As the MBN nanoparticles do not require complicated drug carriers and the materials are bio-compatible, the system has potential to boost successful drug development, according to first author Dr Wanjun Xu.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Pfizer ducks out of Sangamo haemophilia A alliance

pharmaphorum

Sangamo is 'surprised and disappointed' by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results

106
106
article thumbnail

Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy

PharmaTimes

Promising results set stage for European marketing authorization

Marketing 108
article thumbnail

Egyptian Drug Authority approves Lilly and EVA’s insulin injection

Pharmaceutical Technology

Eli Lilly and EVA Pharma have announced approval from the Egyptian Drug Authority for the human insulin glargine injection.

Pharma 105
article thumbnail

Nuvig Therapeutics Nabs $161M to Build Case for a Better Approach to Autoimmune Disease

MedCity News

The startup’s first disease target is chronic inflammatory demyelinating polyneuropathy (CIDP), which can be treated with a blockbuster Argenx drug. Nuvig aims to show its drug can offer a better way to treat this disease and other autoimmune conditions. The post Nuvig Therapeutics Nabs $161M to Build Case for a Better Approach to Autoimmune Disease appeared first on MedCity News.

Biopharma 118
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.